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Background: Gene expression profiling of breast cancers identifies distinct molecular subtypes that affect
prognosis. The aim of this study was to determine whether features of tumors especially the risks of lymph node
(LN) metastases differ among molecular subtypes.
Methods: Subtypes were classified by immunohistochemical surrogates as luminal A, luminalHer2−, luminalHer2+,
TNBC, and HER-2+. Data were obtained from an established, registered database of patients with invasive breast
cancer treated at our hospital between July 2012 and October 2014. A total of 929 tumors were classifiable into
molecular subtypes.
Results: The distribution of subtypes was luminal A (24.2 %), luminalHer2− (27.8 %), luminalHer2+ (9.1 %), TNBC
(21.3 %), and HER-2+ (17.5 %). Marked differences in age, tumor size, extent of lymph node involvement, and grade
were observed among subtypes. On univariate analysis, the LN positivity varied across subtypes with 33.6 % in
luminal A, 40.3 % in luminalHer2−, 37.3 % in luminalHer2+, 37.6 % in TNBC, and 47.4 % in HER-2+ (p = 0.201). There
was no significant difference in LN positivity among subtypes. On multivariable analysis, grade and tumor size were
independent predictors of LN positivity.
Conclusions: Predictors of LN metastases include higher grade and larger tumor size. Even though breast cancer
subtype is not a statistically significant predictor of LN positivity, this information may still be useful in selecting the
appropriate therapy in clinical practice.Background
Gene expression profiling based on 496 genes has iden-
tified distinct molecular subtypes of breast cancer that
differ in prognosis. Studies have demonstrated that pa-
tients with HER-2+ (human epidermal growth factor
receptor-2+) and TNBC (triple negative breast cancer)
tumors have poorer survival compared with patients
with luminal A and luminal B (luminalHer2− and lumi-
nalHer2+) tumors and that those with luminal A tumors
have a better prognosis than those with luminal B tu-
mors [1, 2]. Molecular subtype seems to be associated
with the risk of local failure for patients treated with
breast-conserving therapy and for those treated with
mastectomy [3, 4]. However, little is known about whether
the presenting characteristics especially the axillary lymph
node status of breast cancer differ by molecular subtype.
As we all know, nodal involvement carries important
prognostic and therapeutic importance. Several predictors* Correspondence: woc099@sina.com
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article, unless otherwise stated.of lymph node metastasis have been described such as
higher grade and larger tumor size [5, 6]. However, the
impact of tumor subtype on axillary status has not been
well established [1, 7–9].
Therefore, our purpose was to determine whether
molecular subtype, as defined by estrogen receptor (ER),
progesterone receptor (PR), Ki-67, and HER-2, correlates
with presenting features of breast cancer, particularly to
evaluate whether it is an independent predictor of axil-
lary lymph node involvement on multivariable analysis.Methods
This study was performed with the approval of The First
Affiliated Hospital of Wenzhou Medical University Review
Board. Review of a prospectively maintained database of
patients evaluated and treated for breast cancer from July
2012 to October 2014 was performed. Patients between
the ages of 25 and 90 years with newly diagnosed stage
I–III breast cancer were identified. Of these, preopera-
tive systemic therapy was excluded.
Patients were categorized according to tumor pheno-
typic subtype using the presence or absence of tumordistributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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A (ER+/PR+, HER2−, Ki67 < 14 % or PR ≥ 20 %), lumi-
nalHer2− (ER+/PR+, HER2−, Ki67 ≥ 14 % or PR < 20 %),
luminalHer2+ (ER+ and HER-2+), TNBC (ER− and PR−
and HER2−), and HER-2+ (ER− and PR− and HER-2+).
The criteria are recommended according to the 13th St.
Gallen International Breast Cancer Conference [10, 11].
ER and PR status was determined on the basis of immu-
nohistochemical (IHC) staining. ER/PR was conceived to
be positive if the percentage of nuclear-staining cancer
cells is no less than 1 % [2, 9, 12]. Tumors were consid-
ered HER-2-positive only if they were scored 3+ by IHC
or if they were HER-2-amplified (ratio ≥2.0) on the basis
of fluorescence in situ hybridization (FISH) [13, 14].
Patient and tumor characteristics evaluated included
age, tumor size, grade, molecular subtype, and nodal in-
volvement. Nodal positivity was then evaluated based on
the number of tumors involving lymph nodes. A positive
node was defined as a lymph node containing any cancer
cells by hematoxylin and eosin stain or cytokeratin posi-
tivity via IHC. This was divided into three groups: 0
node positive, 1–3 nodes positive, and ≥4 nodes positive.
Characteristics that would result in nodal positivity were
then evaluated and analyzed. These included patient age,
tumor size, and breast cancer subtype.Table 1 Patient demographic and tumor data
Feature Luminal A luminalHer2− lum
Number, n (%) 225 (24.2) 258 (27.8) 85
Age at diagnosis
Mean ± SD 52.2 ± 12.1 52.3 ± 12.5 49.
Tumor size (cm)
Mean ± SD 2.0 ± 1.1 2.3 ± 1.4 2.4
Size distribution
No. missing 7 4 1
T1 (<2 cm) 119 (54.6) 101 (39.8) 39
T2 (2~5 cm) 95 (43.6) 144 (56.7) 41
T3 (>5 cm) 4 (1.8) 9 (3.5) 4 (
Grade, n (%)
No. missing 19 25 6
1 63 (30.6) 28 (12.0) 5 (
2 127 (61.7) 166 (71.2) 53
3 16 (7.8) 39 (16.7) 21
Node status
No. missing 8 20 2
Total positive 73 (33.6) 96 (40.3) 31
N0 (0) 144 (66.4) 142 (59.7) 52
N1 (1~3) 48 (22.1) 53 (22.3) 15
N2 (≥4) 25 (11.5) 43 (18.1) 16
Bold values are statistically significant (p < 0.05)
SD standard deviationThe χ2 test was used for binary variables and analysis
of variance for continuous variables to compare the dis-
tribution of clinicopathologic characteristics among the
four subtypes. All percentages and statistical tests were
based on available data. Multivariate logistic regression
analysis was used to determine whether subtype was
independently predictive of nodal involvement after con-
trolling for age (continuous), tumor size (continuous),
and tumor grade (3 vs. 2 vs. 1). Luminal A was the refer-
ence group. Patients with missing data were excluded
from multivariate analysis. All statistical tests were two-
sided, and a p value of <0.05 was considered significant.
All statistical analyses were performed using SAS version
9.1 (SAS Institute, Cary, NC).
Results
A total of 929 patients met the study criteria. Of these,
100 underwent breast-conserving surgery (BCS) and 829
were treated with mastectomy. The mean patient age
was 52 (range, 25–90) years. Luminal A tumors were
present in 24.2 %, luminalHer2− in 27.8 %, luminalHer2+
in 9.1 %, TNBC in 21.3 %, and HER-2+ in 17.5 %. Patient
and tumor characteristics by subtype are summarized in
Table 1. Among the four breast cancer subtypes, there
were significant differences in the distribution of tumorinalHer2+ TNBC Her-2+ p value
(9.1) 198 (21.3) 163 (17.5)
7 ± 10.1 52.1 ± 11.9 52.4 ± 10.4 0.433
± 1.4 2.5 ± 1.8 2.5 ± 1.5 0.001
4 3
(46.4) 70 (36.1) 55 (33.4) 0.002
(48.8) 117 (60.3) 96 (60.0)
4.8) 7 (3.6) 9 (5.6)
15 11
6.3) 9 (4.9) 11 (7.2) <0.0001
(67.1) 80 (43.7) 67 (44.1)
(26.6) 94 (51.4) 74 (48.7)
12 9
(37.3) 70 (37.6) 73 (47.4)
(62.7) 116 (62.4) 81 (52.6) 0.201
(18.1) 39 (21.0) 39 (25.3)
(19.3) 31 (16.7) 34 (22.1)
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tumors were smaller when compared to luminalHer2−,
luminalHer2+, TNBC, and HER-2+ tumors (2.0 vs. 2.3,
2.3, 2.4, and 2.5; p = 0.001). Tumors overexpressing HER-2
(luminalHer2+ and HER-2+) and TNBC subtypes were
more frequently in grade 3 and T3. HER-2+ tumors were
more likely to have involvement of nodes. LN metastases
were detected in 343 (39.1 %) patients. The LN positivity
rate varied across subtypes with 73 of 217 (33.6 %) pa-
tients in luminal A, 96 of 238 (40.3 %) in luminalHer2−,
31 of 83 (37.3 %) in luminalHer2+, 70 of 186 (37.6 %) in
TNBC, and 73 of 154 (47.4 %) in HER-2+. In addition,
luminal A breast cancers were more frequently node-
negative when compared to the others (66.4 vs. 59.7, 62.7,
62.4, and 52.6 %, respectively) and less frequently had four
or more positive nodes (11.5 vs. 18.1,19.3,16.7 and 22.1 %,
respectively) (Fig. 1). However, on univariate analysis,
these data suggest that there was no significant difference
in the incidence of nodal metastases among the four
breast cancer subtypes (p = 0.201).
On multivariate analysis, after controlling for tumor
size, grade, and patient age, subtype was not a statisti-
cally significant predictor of nodal metastases (p = 0.227
in ≥1 positive LN and p = 0.561 in ≥4 positive LN;
Table 2). When compared to the luminal A subtype, the
odds ratio for LN positivity in HER-2+ was 1.2, with
95 % CI of 0.6–2.1, suggesting that HER-2+ has nodal
involvement more frequently. However, none of the
other subtypes was found to differ statistically signifi-
cantly from the luminal A subtype in the increased risk
of any nodal metastases. Furthermore, predictors of four
or more positive nodes included size of the tumor of
about 2~5 and >5 cm (odds ratio [OR] 2.4, 1.5–4.0, and
OR 6.2, 1.5–26.4) (p = 0.001), and grade 2 or 3 tumors
(OR 17.5, 2.4–130.5 and OR 22.9, 3.0–176.3) (p = 0.015).
Age was not associated with an increased likelihood of
positive lymph nodes. Larger size and higher grade were
again found to be predictive of having one or more posi-
tive nodes. In addition, when evaluating the predictorsFig. 1 Number of total positive LN by subtype (p = 0.201). N0 vs. N1 vs. N2
and Her-2+of ≥4 positive nodes, tumors overexpressing HER-2
(luminalHer2+ and HER-2+) were more likely to have
four or more nodes positive (OR 1.1, 0.5–2.7 and OR
1.4, 0.7–3.0) (Table 2).
Discussion
In this study, we found an unexpected result when com-
paring initial presenting characteristics of invasive breast
cancer. On univariate analysis, factors associated with
poor prognosis such as grade 3 and T3 were all far more
frequent in tumors that overexpressed HER-2 and TNBC.
On multivariate analysis, subtype was not a statistically
significant predictor of any nodal involvement and high-
volume nodal involvement (four or more positive lymph
nodes). However, the HER-2+ subtype has nodal involve-
ment more frequently when compared with the luminal A
subtype.
Nodal status is an important factor associated with
survival in breast cancer patients, and it is a major deter-
minant factor in decision about therapy. Tumor size,
tumor grade, tumor location, presence of lymphatic/vas-
cular invasion, age at diagnosis, estrogen receptor status
(ER), progesterone receptor status (PR), and HER-2 status
have been previously published as independent variables
for LN positivity [15–17]. Axillary lymph node involve-
ment remains the most important prognostic factor in
early-stage breast cancer. The observed higher frequency
of node metastases in HER-2+ may account for the higher
rates of local recurrence observed in HER-2-positive
tumors. Nguyen et al. [3] recently studied 793 patients
with invasive breast cancer of different molecular subtypes
and treated with surgery and radiotherapy. The rate of
local recurrence was 0.8 % for the luminal A subtype,
1.5 % for luminal B, 7.1 % for the TNBC group, and 8.4 %
for the HER-2+ subtype. Even though there is no statisti-
cally significant difference among subtypes in lymph node
metastases, our findings of increased nodal involvement
in HER-2+ subtypes may at least partly explain the ob-
served increase in local recurrence in the HER-2+ subtype. More N0 in luminal A/TNBC, more N2 in luminalHer−, luminalHer+,
Table 2 Multivariable logistic regression
Variable ≥1 Positive LN (N = 343) ≥4 Positive LN (N = 149)
OR (95 % CI) p value OR (95 % CI) p value
Subtypeª 0.227 0.561
Luminal A 1 1
luminalHer2− 0.7 (0.4–1.2) 1.0 (0.5–2.0)
luminalHer2+ 0.7 (0.4–1.4) 1.1 (0.5–2.7)
TNBC 0.7 (0.4–1.2) 0.8 (0.4–1.7)
Her-2+ 1.2 (0.6–2.1) 1.4 (0.7–3.0)
Tumor size (cm) <0.0001 0.001
<2 1 1
2~5 2.3 (1.6–3.4) 2.4 (1.5–4.0)
>5 2.7 (0.7–10.2) 6.2 (1.5–26.4)
Grade <0.0001 0.015
1 1 1
2 5.6 (2.8–11.2) 17.5 (2.4–130.5)
3 4.5 (2.1–9.8) 22.9 (3.0–176.3)
Age level 0.548 0.676
<50 1 1
50–79 0.9 (0.6–1.3) 1.1 (0.7–1.8)
>79 2.1 (0.3–13.1) 2.1 (0.3–13.8)
Bold values are statistically significant (p < 0.05)
LN lymph node, OR odds ratio
ªSubtypes as defined as luminal A (ER+/PR+, HER2−, Ki67 < 14 % or PR ≥ 20 %),
luminalHer2− (ER+/PR+, HER2−, Ki67 ≥ 14 % or PR < 20 %), luminalHer2+
(ER+ and HER-2+), TNBC (ER− and PR− and HER2−) and HER-2+ (ER− and PR−
and HER-2+)
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study by Crabb et al. [18] that indicates that the TNBC
subtype is associated with a lower incidence of axillary
nodal involvement than other subtypes in four or more
metastatic lymph nodes despite its poor prognosis. Mean-
while, it reported that the luminal B and HER-2+ subtypes
did not predict a different risk of axillary lymph node
involvement compared to the luminal A group. Our data
support this finding, and we found that the HER-2+ sub-
type is associated with a higher likelihood of axillary me-
tastases, despite not identifying a higher risk of having any
positive nodes.
Even so, there are potential implications for the evalu-
ation of patients for local therapy. In general, patients
are fit for breast-conserving surgery with a high degree
of accuracy by history, physical examination, and diag-
nostic mammography [19]. We found that patients over-
expressing HER-2 (luminalHer2+ and HER-2+) and
TNBC subtypes were more frequently in grade 3 and
T3, and those overexpressing the HER-2+ subtype were
more likely to have involvement of nodes, suggesting
that these patients who are borderline candidates for breast
conservation as a result of a large tumor size relative to thebreast size would particularly likely benefit from neoadju-
vant therapy that includes trastuzumab. This treatment has
reported high pathologic complete response rates with
the approach [20]. Discovery of nodal status before neo-
adjuvant therapy with axillary ultrasound and fine-
needle aspiration may also be particularly profitable for
the Her-2+ subtype with greater likelihood of involve-
ment. This means most of these patients will benefit
from chest wall irradiation when mastectomy is per-
formed, and the time and cost of sentinel node biopsy
could be saved even for someone who is not receiving
neoadjuvant therapy.
Although the idea of using molecular subtype to select
local therapy is appealing, we are not suggesting that the
HER-2+ or luminalHer2+ subgroups be preferentially
treated by mastectomy. Randomized trials have demon-
strated that the addition of trastuzumab to chemo-
therapy decreases local failure by approximately 50 %
compared with treatment with chemotherapy alone, so it
is likely that rates of local failure in these groups have
decreased [9]. In addition, Kyndi et al. [4] examined the
risks of locoregional recurrence after mastectomy with
and without radiotherapy based on the subtype classifi-
cation, and they found higher rates of failure in HER-2+
than others. Collectively, these findings suggest that
HER-2 status (in the absence of trastuzumab treatment)
is a poor prognostic factor but is still not predictive of
appropriate local therapy.
Our findings support those of Wiechmannet al. [21],
showing that after controlling for patient age, tumor
size, and grade, TNBC had an OR of 0.7 for one or more
positive nodes and 0.8 for ≥4 metastatic lymph nodes.
The relative likelihood of lymph node involvement,
which is considered a poor prognostic indicator, is
lower for TNBC compared to other breast cancer
subtypes in four or more metastatic lymph nodes. It
is suggested by this finding that the aggressive nature
of TNBC is not directly associated with lymphatic
spread, and it is consistent with the findings of other
studies [7, 18, 21–24].
Tumor size was known as the most significant pre-
dictor of LN metastases [25, 26]. Similarly, our study
demonstrated tumor size as a significant independent
predictive factor for positive LN status with an odds
ratio of 2.3 for T2 vs. T1 tumors and 2.7 for T3 vs. T1
tumors. In other studies, Mustafa et al. [27], when
reviewing more than 2100 patients with ≤1 cm invasive
tumors, show by multivariate analyses that not only the
size of the tumor, but also the grade of the tumor and
the patient’s age are related to the incidence of nodal
involvement. However, we only found that in tumors of
all sizes, higher grade was predictive of nodal positivity.
Age is not associated with increased likelihood of nodal
metastases [25, 26, 28].
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The results of our study are unexpected which suggest pre-
dictors of LN metastases only include higher grade and lar-
ger tumor size, and breast cancer subtype is not a
statistically significant predictor of LN positivity. Even so,
this information may still be useful in clinical practice. We
found tumors overexpressing HER-2 (luminalHer2+ and
HER-2+) and TNBC subtypes were more likely in grade 3
and T3 and HER-2+ tumors were associated more fre-
quently with involved nodes. These are beneficial to make
decisions regarding neoadjuvant therapy, breast-conserving
therapy, axillary surgery, and locoregional radiation.
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